Cancer Specialist (Oncologist), Hematology and Oncology Specialist
Dr. George is a clinical investigator and educator with a focus on gastrointestinal malignancies and new cancer therapy development. As director of the GI Oncology Program at the University of Florida, Dr. George helps to oversee the treatment of all patients with GI malignancies. He also oversees the development and testing of new cancer treatments through clinical trials leveraging advancements in precision oncology and immunotherapy. He previously served as chair of the Medical Advisory Board to the State of Florida Department of Health and the Screen for Life Colorectal Cancer Screening Program, which targets historically underserved populations. He also recently completed a 10 year term as the gubernatorial-appointed chair of the Florida Cancer Control and Research Advisory Council, which advises the legislature, Department of Health, and state surgeon general on all cancer related matters and policy. He currently serves as the Deputy Director of the UF Health Cancer Institute. Through participation with large oncology clinical trial cooperative groups and the National Cancer Institute, Dr. George is an active clinician and clinical investigator in GI malignancies and early phase clinical trials testing new therapies for patients with advanced cancers. He is a member of the medical honor society Alpha Omega Alpha, the American Society of Clinical Oncology, and numerous cancer research groups.
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
See all insurancesHigh blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic…
This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan) works…
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their…
Speaker: Thomas George, MD, FACP, FASCOMedical OncologistDeputy Director UF Health Cancer CenterDirector of GI Oncology Program
December 11, 2023
For many patients diagnosed with cancer, the burden extends well beyond the clinic walls, as out-of-pocket medical costs and travel expenses add up. Many…
College of Medicine, UF Health Cancer Institute, +2 more
July 13, 2023
The University of Florida Health Cancer Center has appointed two accomplished oncologists to key executive leadership roles, positioning the center to reach…
Department of Urology, +4 more
